EP Lab Digest - April 2008 - (Page 24)

24 EP GUIDELINES APRIL 2008 A Summary of the ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Flutter Linda C. Moulton, RN, MS Owner, Critical Care ED and C.C.E. Consulting Faculty, Order and Disorder Electrophysiology Training Program Springfield, Illinois The population chosen for this performance measure was patients aged 18 or older with nonvalvular AF or atrial flutter. The performance measurement set for this group includes: assessment of thromboembolic risk factors, chronic anticoagulation therapy, and monthly INR measurement. A sample data collection instrument is available with this document, and the entire document may be downloaded from the American College of Cardiology website at www.acc.org. Monthly INR Measurement The measurement of INR on a monthly basis for those on warfarin is included in the 2006 guidelines. The performance measure data collection tool includes columns for monthly recording of the date of INR, INR value, current warfarin dose, and review of concurrent medications. The performance measures for AF and atrial flutter and the tool provided for measurement of these elements within the clinical practice setting represent an effort to continually improve the care we deliver to this population. The committee recognized within their document that 100% compliance can probably never be achieved; however, they have provided an instrument that will help the clinician assess where their practice is and attain a method for evaluating improvement. For more information about these guidelines, please see: http://content.onlinejacc.org/cgi/content/full/ 51/8/865 Assessment of Thromboembolic Risk Factors The assessment of thromboembolic risk is guided by use of the CHADS2 index. This index utilizes a point system to derive a designated risk level for thromboembolism for a given patient. Factors incorporated into this scoring are previous stroke or TIA (a high risk factor), history of hypertension, heart failure or impaired left ventricular systolic function, age of > 75, and diabetes mellitus. Factors other than stroke/TIA were considered moderate risk factors. References Chronic Anticoagulation Therapy Determination of appropriate anticoagulation therapy is based on each individual’s assigned risk score. The 2006 guidelines broke this into three levels: low, intermediate, and high risk.Those with low risk had no identified risk factors from the CHADS2 assessment, and the recommendation was that these patients should receive 81–325 mg of aspirin daily. The intermediate risk patient had one moderate risk factor, and was to be placed on aspirin (81 to 325 mg daily) or warfarin (INR 2.0 to 3.0, target 2.5). High-risk patients were those with any high-risk factor or more than one moderate risk factor. Recommended therapy for this group is warfarin (INR 2.0 to 3.0, target 2.5). trial fibrillation (AF) continues to be the most frequently occurring arrhythmia in clinical practice. Its presence increases the risk of stroke, heart failure and all-cause mortality. In 2006, ACC/AHA/ESC practice guidelines were published for the management of AF.1 This was the first step of a multifaceted plan for improving the quality of care delivered to this high-risk group. The second step is the development of performance measures. A review of the recently published performance measures document follows. A The ‘ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration with the Heart Rhythm Society’ document was published in the Journal of the American College of Cardiology in February.2 The writing committee included senior clinicians, specialists in cardiac electrophysiology, and representatives from the American College of Cardiology, the American Heart Association, the European Society of Cardiology, the American Medical Association, the American College of Physicians, and the Heart Rhythm Society. The clinical population for whom the performance measures were written includes those 18 years or older with nonvalvular AF seen in outpatient settings. The measures are not meant for those with acute, reversible causes of AF or flutter, those with mitral stenosis or prosthetic heart valves, or those who are pregnant. 1. Fluster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) [published correction appears in J Am Coll Cardiol 2007;50:562]. J Am Coll Cardiol 2006;48:854-906. 2. Estes NAM, Halperin JL, Calkins H, et al. ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration With the Heart Rhythm Society. J Am Coll Cardiol 2008;51:865-884. The Process The process used by the group for developing performance measures involved multiple stages. First AF and atrial flutter were defined for the purposes of this measure.Then there was a determination of dimensions of care to be evaluated, categorization of performance measures within the relevant dimensions of care, and identification of areas where evidence was lacking. Extensive literature review was utilized throughout the process. Prevention of thromboembolism was selected as the focus for this set of performance measures. The performance measures for AF and atrial flutter and the tool provided for measurement of these elements within the clinical practice setting represent an effort to continually improve the care we deliver to this population. http://www.acc.org http://content.onlinejacc.org/cgi/content/full/51/8/865

Table of Contents Feed for the Digital Edition of EP Lab Digest - April 2008

EP Lab Digest - April 2008 Pediatric Electrophysiology Medical Relief Work on the Yucatan Peninsula: A Labor of Love EP 101: Considerations for the Elderly EP Patient Contents Letter from the Editor Spotlight Interview: University of Maryland A Summary of the ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Flutter Can Psychosocial Characteristics Predict Fatal Outcomes in Patients? Interview with Jonathan S. Steinberg, MD, FACC 10-Minute Interview: Diane D. Sheffield, RN, BSN AED Access for All: An Organization for SCA Survivors New Column: 5 Quick Clues to AV Nodal Reentry Tachycardia CMS 2008 OPPS Final Rule Review New Online AED and CPR Training Opportunities: Q & A with Keith Weaver Highlights from the 5th Annual International Arrhythmia Winter School Email Discussion Group Events Calendar Second Annual Salary Survey Industry News and Products Classifieds Advertisers Index

EP Lab Digest - April 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.